Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 314-330
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.314
Table 2 Basic information of patients expressing ABCG2, n (%)
Characteristic
Category
Low expression of ABCG2, n = 322
High expression of ABCG2, n = 322
P value
T stageT115 (2.3)5 (0.8)0.114
T254 (8.4)57 (8.9)
T3219 (34.2)217 (33.9)
T433 (5.1)41 (6.4)
N stageN0209 (32.7)159 (24.8)< 0.001
N176 (11.9)77 (12.0)
N236 (5.6)83 (13.0)
M stageM0239 (42.4)236 (41.8)0.111
M136 (6.4)53 (9.4)
Primary therapy outcomePD12 (3.8)21 (6.7)0.305
SD2 (0.6)3 (1.0)
PR10 (3.2)6 (1.9)
CR129 (41.3)129 (41.3)
SexFemale143 (22.2)158 (24.5)0.269
Male179 (27.8)164 (25.5)
CEA level≤ 5127 (30.6)134 (32.3)0.986
> 574 (17.8)80 (19.3)
Perineural invasionNo90 (38.3)85 (36.2)0.351
Yes26 (11.1)34 (14.5)
Lymphatic invasionNo192 (33.0)158 (27.1)0.007
Yes100 (17.2)132 (22.7)
History of colon polypsNo182 (32.8)195 (35.1)0.510
Yes92 (16.6)86 (15.5)
Neoplasm typeColon adenocarcinoma244 (37.9)234 (36.3)0.417
Rectum adenocarcinoma78 (12.1)88 (13.7)
Age in yr, median (IQR)68.0 (59.0, 75.8)68.0 (57.3, 76.0)0.423